Total patients with related AEs
|
2 (67)
|
1 (33)
|
2 (67)
|
1 (33)
|
30 (79)
|
3 (8)
|
34 (77)
|
5 (11)
|
39 (89)
|
General disorders and administration site reactions
|
2 (67)
|
1 (33)
|
3 (100)
|
0
|
32 (84)
|
0
|
37 (84)
|
1 (2)*1
|
38 (86)
|
Injection site erythema
|
2 (67)
|
0
|
2 (67)
|
0
|
23 (61)
|
0
|
27 (61)
|
0
|
27 (61)
|
Injection site reaction
|
2 (67)
|
0
|
1 (33)
|
0
|
18 (47)
|
0
|
21 (48)
|
0
|
21 (48)
|
Fatigue
|
2 (67)
|
0
|
0
|
0
|
6 (16)
|
0
|
8 (18)
|
0
|
8 (18)
|
Pyrexia
|
0
|
0
|
1 (33)
|
0
|
6 (16)
|
0
|
7 (16)
|
0
|
7 (16)
|
Chills
|
1 (33)
|
0
|
0
|
0
|
4 (11)
|
0
|
5 (11)
|
0
|
5 (11)
|
Influenza-like symptoms
|
0
|
0
|
0
|
0
|
5 (13)
|
0
|
5 (11)
|
0
|
5 (11)
|
Musculoskeletal and connective tissue disorders3
|
1 (33)
|
0
|
0
|
0
|
5 (13)
|
1 (3)
|
6 (14)
|
1 (2) *2
|
7 (16)
|
Nervous system disorders4
|
1 (33)
|
0
|
1 (33)
|
0
|
4 (11)
|
0
|
6 (14)
|
0
|
6 (14)
|
Renal and urinary disorders5
|
0
|
0
|
0
|
1 (33)
|
3 (8)
|
2 (5)
|
3 (7)
|
3 (7)*3
|
6 (14)
|
Skin and subcutaneous disorders6
|
0
|
0
|
0
|
0
|
6 (16)
|
0
|
6 (14)
|
0
|
6 (14)
|
Gastrointestinal disorders7
|
1 (33)
|
0
|
0
|
0
|
3 (8)
|
1 (3)
|
4 (9)
|
1 (2)*4
|
5 (11)
|